Logo image of IRWD

IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Fundamental Analysis

NASDAQ:IRWD - Nasdaq - US46333X1081 - Common Stock - Currency: USD

0.7523  -0.02 (-3.04%)

After market: 0.7408 -0.01 (-1.53%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IRWD. IRWD was compared to 557 industry peers in the Biotechnology industry. IRWD has only an average score on both its financial health and profitability. IRWD is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year IRWD has reported negative net income.
In the past year IRWD had a positive cash flow from operations.
Of the past 5 years IRWD 4 years were profitable.
Each year in the past 5 years IRWD had a positive operating cash flow.
IRWD Yearly Net Income VS EBIT VS OCF VS FCFIRWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -9.88%, IRWD belongs to the top of the industry, outperforming 84.20% of the companies in the same industry.
The Return On Invested Capital of IRWD (20.86%) is better than 97.67% of its industry peers.
IRWD had an Average Return On Invested Capital over the past 3 years of 36.95%. This is significantly above the industry average of 14.78%.
The 3 year average ROIC (36.95%) for IRWD is well above the current ROIC(20.86%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -9.88%
ROE N/A
ROIC 20.86%
ROA(3y)-65.53%
ROA(5y)-26.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)36.95%
ROIC(5y)30.66%
IRWD Yearly ROA, ROE, ROICIRWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

In the last couple of years the Profit Margin of IRWD has declined.
With an excellent Operating Margin value of 23.20%, IRWD belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
In the last couple of years the Operating Margin of IRWD has remained more or less at the same level.
IRWD does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 23.2%
PM (TTM) N/A
GM N/A
OM growth 3Y-21.4%
OM growth 5Y0.07%
PM growth 3Y-87.48%
PM growth 5Y-45.09%
GM growth 3YN/A
GM growth 5YN/A
IRWD Yearly Profit, Operating, Gross MarginsIRWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRWD is creating value.
The number of shares outstanding for IRWD has been increased compared to 1 year ago.
Compared to 5 years ago, IRWD has more shares outstanding
Compared to 1 year ago, IRWD has a worse debt to assets ratio.
IRWD Yearly Shares OutstandingIRWD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IRWD Yearly Total Debt VS Total AssetsIRWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -5.18, we must say that IRWD is in the distress zone and has some risk of bankruptcy.
IRWD has a worse Altman-Z score (-5.18) than 61.22% of its industry peers.
The Debt to FCF ratio of IRWD is 7.45, which is on the high side as it means it would take IRWD, 7.45 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.45, IRWD belongs to the top of the industry, outperforming 92.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 7.45
Altman-Z -5.18
ROIC/WACC3.52
WACC5.92%
IRWD Yearly LT Debt VS Equity VS FCFIRWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

A Current Ratio of 3.34 indicates that IRWD has no problem at all paying its short term obligations.
IRWD has a Current ratio of 3.34. This is in the lower half of the industry: IRWD underperforms 61.22% of its industry peers.
IRWD has a Quick Ratio of 3.34. This indicates that IRWD is financially healthy and has no problem in meeting its short term obligations.
IRWD has a Quick ratio (3.34) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.34
IRWD Yearly Current Assets VS Current LiabilitesIRWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for IRWD have decreased strongly by -127.03% in the last year.
IRWD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.27% yearly.
Looking at the last year, IRWD shows a very negative growth in Revenue. The Revenue has decreased by -23.18% in the last year.
Measured over the past years, IRWD shows a decrease in Revenue. The Revenue has been decreasing by -3.88% on average per year.
EPS 1Y (TTM)-127.03%
EPS 3Y-74.31%
EPS 5Y-48.27%
EPS Q2Q%-600%
Revenue 1Y (TTM)-23.18%
Revenue growth 3Y-5.3%
Revenue growth 5Y-3.88%
Sales Q2Q%-45.05%

3.2 Future

IRWD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -60.56% yearly.
The Revenue is expected to decrease by -15.48% on average over the next years. This is quite bad
EPS Next Y843.5%
EPS Next 2Y142.18%
EPS Next 3Y-92.2%
EPS Next 5Y-60.56%
Revenue Next Year-23.71%
Revenue Next 2Y-14.82%
Revenue Next 3Y-20.24%
Revenue Next 5Y-15.48%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IRWD Yearly Revenue VS EstimatesIRWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
IRWD Yearly EPS VS EstimatesIRWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRWD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 6.41, the valuation of IRWD can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRWD indicates a rather cheap valuation: IRWD is cheaper than 98.20% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IRWD to the average of the S&P500 Index (21.76), we can say IRWD is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.41
IRWD Price Earnings VS Forward Price EarningsIRWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IRWD is valued cheaply inside the industry as 97.85% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRWD indicates a rather cheap valuation: IRWD is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1.55
EV/EBITDA 7.94
IRWD Per share dataIRWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of IRWD may justify a higher PE ratio.
IRWD's earnings are expected to decrease with -92.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y142.18%
EPS Next 3Y-92.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRWD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRONWOOD PHARMACEUTICALS INC

NASDAQ:IRWD (7/11/2025, 8:25:04 PM)

After market: 0.7408 -0.01 (-1.53%)

0.7523

-0.02 (-3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners97.48%
Inst Owner Change0%
Ins Owners2.59%
Ins Owner Change11.74%
Market Cap121.74M
Analysts50
Price Target0.97 (28.94%)
Short Float %4.86%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-134.52%
Min EPS beat(2)-194.1%
Max EPS beat(2)-74.94%
EPS beat(4)0
Avg EPS beat(4)-111.18%
Min EPS beat(4)-194.1%
Max EPS beat(4)-74.94%
EPS beat(8)1
Avg EPS beat(8)-85.06%
EPS beat(12)3
Avg EPS beat(12)-59%
EPS beat(16)5
Avg EPS beat(16)-43.94%
Revenue beat(2)0
Avg Revenue beat(2)-8.83%
Min Revenue beat(2)-12.28%
Max Revenue beat(2)-5.38%
Revenue beat(4)0
Avg Revenue beat(4)-8.19%
Min Revenue beat(4)-13.51%
Max Revenue beat(4)-1.59%
Revenue beat(8)1
Avg Revenue beat(8)-8.12%
Revenue beat(12)2
Avg Revenue beat(12)-6.59%
Revenue beat(16)5
Avg Revenue beat(16)-4.15%
PT rev (1m)-81.49%
PT rev (3m)-89.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.08%
EPS NY rev (1m)-2.63%
EPS NY rev (3m)6.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.41
P/S 0.38
P/FCF 1.55
P/OCF 1.55
P/B N/A
P/tB N/A
EV/EBITDA 7.94
EPS(TTM)-0.1
EYN/A
EPS(NY)0.12
Fwd EY15.59%
FCF(TTM)0.48
FCFY64.41%
OCF(TTM)0.49
OCFY64.5%
SpS1.96
BVpS-2.06
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.88%
ROE N/A
ROCE 26.41%
ROIC 20.86%
ROICexc 34.13%
ROICexgc 34.67%
OM 23.2%
PM (TTM) N/A
GM N/A
FCFM 24.68%
ROA(3y)-65.53%
ROA(5y)-26.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)36.95%
ROIC(5y)30.66%
ROICexc(3y)70.13%
ROICexc(5y)67.75%
ROICexgc(3y)71.88%
ROICexgc(5y)68.8%
ROCE(3y)46.77%
ROCE(5y)38.81%
ROICexcg growth 3Y-13.6%
ROICexcg growth 5Y-7.25%
ROICexc growth 3Y-13.97%
ROICexc growth 5Y-7.41%
OM growth 3Y-21.4%
OM growth 5Y0.07%
PM growth 3Y-87.48%
PM growth 5Y-45.09%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 7.45
Debt/EBITDA 7.72
Cap/Depr 5.31%
Cap/Sales 0.03%
Interest Coverage 250
Cash Conversion 103.74%
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.34
Altman-Z -5.18
F-Score6
WACC5.92%
ROIC/WACC3.52
Cap/Depr(3y)21726.6%
Cap/Depr(5y)13049.4%
Cap/Sales(3y)77.3%
Cap/Sales(5y)46.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.03%
EPS 3Y-74.31%
EPS 5Y-48.27%
EPS Q2Q%-600%
EPS Next Y843.5%
EPS Next 2Y142.18%
EPS Next 3Y-92.2%
EPS Next 5Y-60.56%
Revenue 1Y (TTM)-23.18%
Revenue growth 3Y-5.3%
Revenue growth 5Y-3.88%
Sales Q2Q%-45.05%
Revenue Next Year-23.71%
Revenue Next 2Y-14.82%
Revenue Next 3Y-20.24%
Revenue Next 5Y-15.48%
EBIT growth 1Y-38.42%
EBIT growth 3Y-25.57%
EBIT growth 5Y-3.82%
EBIT Next Year13.33%
EBIT Next 3Y-27.49%
EBIT Next 5Y-15.42%
FCF growth 1Y-72.93%
FCF growth 3Y-26.61%
FCF growth 5Y96.83%
OCF growth 1Y-72.91%
OCF growth 3Y-26.6%
OCF growth 5Y57.45%